Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Sponsor
Ruijin Hospital
Study ID
NCT06573138
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Lymphoma, Extranodal NK-T-Cell

Eligibility Criteria

Sex
ALL
Age
14 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Key Dates

Start date
Sep 1, 2024
Status verified
Aug 2024
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chemofree
    Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus Golidocitinib.

Primary Outcome Measure

Best CRR [ Time Frame: through study completion, an average of 1 year ]

Central Contacts